Why Odyssey Therapeutics, Inc.’s (ODTX) Stock Is Up 6.73%
As of Friday, October 09, Odyssey Therapeutics, Inc.’s ODTX share price has surged by 6.73%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of interferon regulatory factor 5 (IRF5); OD-003, a protein therapeutic designed to agonize tumor necrosis factor receptor 2 selectively on Treg; a TSLP/IL-33 bispecific antagonist; an oral small molecule interleukin-1 receptor–associated kinase 4 scaffolding inhibitor; and a small molecule inhibitor of IRF5. The company was incorporated in 2021 and is headquartered in Boston, Massachusetts.
Commentary & Analysis
Why Odyssey Therapeutics, Inc.’s (ODTX) Stock Is Down 7.97%
As of Tuesday, October 06, Odyssey Therapeutics, Inc.’s ODTX share price has dipped by 7.97%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Odyssey Therapeutics, Inc.’s (ODTX) Stock Is Down 6.70%
As of Thursday, September 24, Odyssey Therapeutics, Inc.’s ODTX share price has dipped by 6.70%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Odyssey Therapeutics, Inc.’s (ODTX) Stock Is Down 5.66%
As of Wednesday, September 23, Odyssey Therapeutics, Inc.’s ODTX share price has dipped by 5.66%, which has investors questioning if this is right time to buy.Michael Rose
Why Odyssey Therapeutics, Inc.’s (ODTX) Stock Is Up 6.09%
As of Friday, September 18, Odyssey Therapeutics, Inc.’s ODTX share price has surged by 6.09%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | ODTX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $795.4 | $218.1 | 43% |
|
| Shares Out (Mil) | 30.3 | 53.9 | 37% |
|
| Institutional Ownership | 94.3% | 93.1% | 65% |
|
| Float (Mil) | 20.1 | 40.9 | 28% |
|
| Beta | na | 0.95 | na |
|
| Avg Daily Volume (000s) | 280 | 611 | 49% |
|
| Price Change (52-week) |
na | 46.3% | na |
|
| Growth | ODTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.8% | na |
|
| Net Income (5yr) | na | (10.2%) | na |
|
| EPS (5yr) | na | 15.7% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.7%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 4 | 4 | |
| Current EPS | ($0.955) | ($4.623) | ($4.150) | |
| Month Ago EPS | ($0.930) | ($4.255) | ($4.360) | |
| # Rev Up | na | 0 | na | |
| # Rev Down | na | 0 | na | |
| Three Months Ago EPS | ($0.890) | ($4.218) | ($3.876) | |
| Year/Year Chg | (45.2%) | (90.8%) | (91.5%) | |
| Financials | ODTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($160) | ($44) | 8% |
|
| EPS (TTM) | ($14.051) | ($1.600) | 3% |
|
| Operating Cash Flow (TTM) (Mil) | ($132) | ($33) | 5% |
|
| Net Cash Flow (TTM) (Mil) | $145 | $2 | 81% |
|
| Long-Term Debt (Q1) (Mil) | $19 | $4 | 32% |
|
| Enterprise Value (Q1) (Mil) | $654 | $177 | 36% |
|
| Valuation | ODTX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.89 | 2.13 | 51% |
|
| P/E | na | 19.3 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | ODTX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.0% | na |
|
| Net Margin | na | (75.3%) | na |
|
| ROA | (41.5%) | (47.2%) | 13% |
|
| ROE | (201.9%) | (54.2%) | 4% |
|
| Liabilities to Assets | 12.9% | 29.1% | 8% |
|
| F-Score | 2 | 3 | na |
|
Odyssey Therapeutics, Inc. did not pass any screens on 10/14/2026.
